KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Other Non Operating Income (2016 - 2026)

Pfizer has reported Other Non Operating Income over the past 18 years, most recently at -$861.0 million for Q1 2026.

  • Quarterly Other Non Operating Income rose 9.65% to -$861.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$6.6 billion through Mar 2026, down 122.29% year-over-year, with the annual reading at -$6.7 billion for FY2025, 53.24% down from the prior year.
  • Other Non Operating Income was -$861.0 million for Q1 2026 at Pfizer, up from -$4.5 billion in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $159.0 million in Q4 2023 and troughed at -$4.5 billion in Q4 2025.
  • The 5-year median for Other Non Operating Income is -$517.0 million (2025), against an average of -$726.6 million.
  • Year-over-year, Other Non Operating Income surged 109.72% in 2023 and then plummeted 1576.0% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $59.0 million in 2022, then soared by 169.49% to $159.0 million in 2023, then tumbled by 252.83% to -$243.0 million in 2024, then plummeted by 1757.61% to -$4.5 billion in 2025, then soared by 80.93% to -$861.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's Other Non Operating Income are -$861.0 million (Q1 2026), -$4.5 billion (Q4 2025), and -$517.0 million (Q3 2025).